产品: RPL7A 抗体
货号: DF9137
描述: Rabbit polyclonal antibody to RPL7A
应用: WB IHC
反应: Human, Mouse, Rat
预测: Zebrafish, Bovine, Sheep, Dog, Chicken, Xenopus
分子量: 30kDa; 30kD(Calculated).
蛋白号: P62424
RRID: AB_2842333

浏览相似产品>>

   规格 价格 库存
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售

产品描述

来源:
Rabbit
应用:
IHC 1:50-1:200, WB 1:1000-3000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human,Mouse,Rat
预测:
Zebrafish(100%), Bovine(100%), Sheep(100%), Dog(100%), Chicken(100%), Xenopus(92%)
克隆:
Polyclonal
特异性:
RPL7A Antibody detects endogenous levels of total RPL7A.
RRID:
AB_2842333
引用格式: Affinity Biosciences Cat# DF9137, RRID:AB_2842333.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

60S ribosomal protein L7a; L7A; MGC103146; PLA X polypeptide; PLA-X polypeptide; ribosomal protein L7a; RL7A_HUMAN; RP23-414L19.4; RPL7A; SURF 3; SURF-3; SURF3; surfeit 3; Surfeit locus protein 3; Thyroid hormone receptor uncoupling protein; TRUP;

抗原和靶标

免疫原:
Uniprot:
基因/基因ID:
序列:
MPKGKKAKGKKVAPAPAVVKKQEAKKVVNPLFEKRPKNFGIGQDIQPKRDLTRFVKWPRYIRLQRQRAILYKRLKVPPAINQFTQALDRQTATQLLKLAHKYRPETKQEKKQRLLARAEKKAAGKGDVPTKRPPVLRAGVNTVTTLVENKKAQLVVIAHDVDPIELVVFLPALCRKMGVPYCIIKGKARLGRLVHRKTCTTVAFTQVNSEDKGALAKLVEAIRTNYNDRYDEIRRHWGGNVLGPKSVARIAKLEKAKAKELATKLG

种属预测

种属预测:

score>80的预测可信度较高,可尝试用于WB检测。*预测模型主要基于免疫原序列比对,结果仅作参考,不作为质保凭据。

Species
Results
Score
Bovine
100
Sheep
100
Dog
100
Zebrafish
100
Chicken
100
Xenopus
92
Pig
0
Horse
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

翻译修饰 - P62424 作为底物

Site PTM Type Enzyme
K11 Ubiquitination
K20 Sumoylation
K20 Ubiquitination
K26 Ubiquitination
K34 Acetylation
K34 Ubiquitination
K37 Ubiquitination
K48 Acetylation
K48 Sumoylation
K48 Ubiquitination
K56 Ubiquitination
Y71 Phosphorylation
K72 Ubiquitination
K75 Ubiquitination
R89 Methylation
K97 Acetylation
K97 Ubiquitination
K101 Acetylation
K101 Ubiquitination
T106 Phosphorylation
K107 Ubiquitination
K121 Ubiquitination
K125 Ubiquitination
K131 Ubiquitination
K150 Acetylation
K150 Ubiquitination
K176 Sumoylation
K176 Ubiquitination
Y181 Phosphorylation
C182 S-Nitrosylation
K185 Ubiquitination
K197 Ubiquitination
T198 Phosphorylation
S209 Phosphorylation
K212 Acetylation
K212 Ubiquitination
K217 Acetylation
K217 Ubiquitination
R223 Methylation
R229 Methylation
Y230 Phosphorylation
R234 Methylation
R235 Methylation
K245 Ubiquitination
K252 Sumoylation
K255 Ubiquitination
K259 Ubiquitination
K264 Sumoylation
K264 Ubiquitination

研究背景

亚基结构:

Interacts with CRY1 (By similarity). Interacts with DICER1, AGO2, TARBP2, MOV10 and EIF6; they form a large RNA-induced silencing complex (RISC).

蛋白家族:

Belongs to the eukaryotic ribosomal protein eL8 family.

研究领域

· Genetic Information Processing > Translation > Ribosome.

文献引用

1). SOX1 acts as a tumor hypnotist rendering nasopharyngeal carcinoma cells refractory to chemotherapy. Cell Death Discovery, 2023 (PubMed: 37369660) [IF=7.0]

Application: WB    Species: Human    Sample: NPC cells

Fig. 1 SOX1 decreases ribosome pathway and DNA replication in NPC cells. A An experimental timeline for doxycycline (Blue block: 0 µg/ml, red block: 1 µg/ml) schedules used to control the expression of SOX1 in cells (HONE1 TRE-SOX1 or CNE2 TRE-SOX1). On day 2 and day 4, the cells were counted and proteins were extracted for protein concentration and western blot analysis, respectively. B Western blot analysis of SOX1, RPS3, RPL7A, and β-actin expression in cells. β-actin was used as a control. C Gene set enrichment analysis (GSEA) of ranked genes from cells. Gene set “hsa03010: Ribosome” of KEGG pathways was presented. NES normalized enrichment score. D Scatter dot plots showing the average protein content per cell. E An experimental timeline for doxycycline (Blue block: 0 µg/ml, red block: 1 µg/ml) schedules used to control the expression of SOX1 in cells (HONE1 TRE-SOX1 or CNE2 TRE-SOX1). Both groups of cells were treated with 20 µM BrdU for varying durations, and on day 4, BrdU-positive cells were determined by flow cytometry analysis. F Histograms showing the percentage of BrdU-negative or -positive cells in “SOX1-High” and “SOX1-Low” groups of cells. G Time courses of the percentage of BrdU-positive cells in BrdU incorporation assays, which were fitted by an exponential plateau equation. H An illustration of model hypothesis that overexpression of SOX1 induces quiescent NPC cells. Dox Doxycycline.

限制条款

产品的规格、报价、验证数据请以官网为准,官网链接:www.affbiotech.com | www.affbiotech.cn(简体中文)| www.affbiotech.jp(日本語)

产品的数据信息为Affinity所有,未经授权不得收集Affinity官网数据或资料用于商业用途,对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整,如您已订购该产品,请以订购时随货说明书为准,否则请以官网内容为准,官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时,请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.